Related Experiment Video
Updated: Jun 29, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Pancreatic cancer: new approaches to drug therapy
1Virginia Mason Hospital and Medical Center, Seattle, Washington, USA.
Abstract:
Outcomes in pancreatic ductal adenocarcinoma (PDAC) remain poor due to a variety of biological, clinical, and societal factors. However, in recent years, PDAC has seen 1) increased precision of initial evaluation, 2) increased emphasis on supportive care, 3) deeper understanding of the translation biology of PDAC, especially as pertains to genomic alterations, and 4) foundational combination chemotherapy clinical trials across all disease stages. These advances have led to a wide range of new approaches to drug therapy for PDAC. Currently available drugs are showing added benefit, both by resequencing them with each other and also with respect to other therapeutic modalities. Molecular strategies are being developed to predict response to known therapeutic agents and to identify others. Additionally, a wide range of new drugs for PDAC are under development, including drugs which inhibit critical molecular pathways, drugs which attempt to capitalize on homologous repair deficiencies, immunotherapeutic approaches, antimetabolic agents, and drugs which attack the extracellular matrix which supports PDAC growth. These new approaches offer the promise of improved survival for future PDAC patients.
Insights
Pancreatic cancer treatment is improving with new combination therapies and molecular strategies. Ongoing research into novel drugs targeting specific pathways and the tumor microenvironment offers hope for better patient survival.
Area of Science:
- Oncology
- Translational Medicine
- Drug Development
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has historically poor outcomes.
- Recent advances include improved diagnostics, supportive care, and understanding of PDAC biology.
- Combination chemotherapy trials have become foundational across all disease stages.
Purpose of the Study:
- To review recent advances in drug therapy for PDAC.
- To highlight emerging therapeutic strategies and drug development pipelines.
- To discuss the potential impact of these advances on patient survival.
Main Methods:
- Review of current literature on PDAC treatment advances.
- Analysis of emerging drug therapies targeting molecular pathways and tumor microenvironment.
- Evaluation of combination chemotherapy and molecular strategies for treatment response prediction.
Main Results:
- Existing drugs show benefit when re-sequenced or combined with other modalities.
- Molecular strategies are being developed for predicting treatment response.
- Numerous novel drugs are in development, including pathway inhibitors, DNA repair-targeted agents, immunotherapies, antimetabolites, and anti-extracellular matrix agents.
Conclusions:
- New therapeutic approaches hold promise for improving survival in pancreatic cancer.
- Advances in understanding PDAC biology are driving innovative treatment strategies.
- The development of targeted therapies and combination treatments represents a significant step forward in managing PDAC.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...